Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
NCT05463848Phase 2Active, not recruiting
- Sponsor
- L. Nicolas Gonzalez Castro
- Start
- Oct 2022
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in glioblastoma (GBM), sponsored by L. Nicolas Gonzalez Castro. Started Oct 2022; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05463848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463848.